$STTK

Shattuck Labs (STTK) plans to start a Phase 2 trial in 2026 for SL-325 in hidradenitis suppurativa, with data expected in 2028. The company also appointed Shoba Ravichandran as Senior Vice President, Clinical Development. Cash runway is expected to last until 2029.

Shattuck Labs (STTK) rose 4.91% after two analysts initiated coverage with positive ratings. TD Cowen rated it buy, while Raymond James gave a strong buy and $18 price target. Both highlighted SL-325, a drug candidate for inflammatory bowel disease, citing its novel mechanism. The company reported $208.3M in cash and expects funding into 2029. Phase 2b trial for SL-325 is set to start in Q3.

Shattuck Labs (STTK) stock rose 4.91% on Monday after two analysts issued positive ratings. TD Cowen initiated coverage with a buy rating, while Raymond James gave a strong buy rating and $18 price target, more than double its recent close of $7.90. The optimism is driven by the company's SL-325 drug, which targets inflammatory bowel disease and has a potential $20 billion market, according to Raymond James.

Analysts made several ratings changes: UBS upgraded Celestica to Buy with a $430 target, citing AI-driven demand. Citi initiated Reformation as Buy with a $20 target. Morgan Stanley initiated Jersey Mike's and ArcelorMittal as Overweight. Baird upgraded Darden to Outperform and downgraded Chipotle to Neutral. Other notable moves include upgrades for Suzano, Ionic Digital, and Fortune Brands, while Canada Goose was downgraded.

H.C. Wainwright cut its price target for Shattuck Labs (NASDAQ:STTK) to $14 from $18 while keeping a Buy rating, after Shattuck reported Q2 2026 results on Aug. 11. Shattuck expanded its RECEPTIVE-CD1 Phase 2b trial to three doses and ~232 patients. The SL-325 Crohn’s trial remains on track for a Q3 2026 start. The article also notes a $75M public offering and warrant exercises.

Shattuck Labs, Inc. (STTK) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights – Phase 1 clinical trial results for SL-325 demonstrated a favorable safety profile, a potentially best-in-mechanism immunogenicity profile, and durable DR3 blockade of TL1A bi

Shattuck Labs (STTK) shares fell 1.8% pre-open after its Q2 2026 earnings. The company reported a net loss of $15.2 million versus $12.5 million a year earlier, and R&D rose 34% to $11.7 million. It cited favorable Phase 1 safety for SL-325 and said Phase 2b in Crohn’s is on track. Cash and investments were about $208.3 million.

Shattuck Labs (NASDAQ: STTK) reported Q2 2026 results and clinical updates for SL-325 and SL-846. SL-325 Phase 1 showed a favorable safety profile, 3.7% antidrug antibodies, and durable TL1A/DR3 blockade; RECEPTIVE-CD1 Phase 2b in Crohn’s is expected to start Q3 2026. Cash and investments were $208.3M, funding operations into 2029.

Shattuck Labs shares rose about 4.8% on Friday, closing near $7.43. The move followed an inaugural note from JPMorgan’s Brian Cheng, who rated STTK overweight and set a $10 price target. The note cited Shattuck’s lead IBD drug candidate SL-325, referencing recent healthy volunteer data on safety and target engagement.

Wall Street analysts issued multiple rating changes. Truist upgraded PayPal (PYPL) to Hold, $57 target; Leerink upgraded Edwards Lifesciences (EW) to Outperform, $101. TD Cowen upgraded Digital Realty (DLR) to Buy, $222; Morgan Stanley upgraded Progressive (PGR) to Equal Weight, $210. Several downgrades followed, including Infosys (INFY) and Albertsons (ACI). Coverage initiations included SpaceX (SPCX) and Chime (CHYM).